Collegium Pharmaceutical Inc’s recently made public that its EVP and Chief Medical Officer Smith Thomas B unloaded Company’s shares for reported $0.67 million on Aug 29 ’25. In the deal valued at $38.42 per share,17,478 shares were sold. As a result of this transaction, Smith Thomas B now holds 70,264 shares worth roughly $2.45 million.
Then, Smith Thomas B bought 17,478 shares, generating $671,576 in total proceeds.
Before that, Dreyer Scott sold 16,389 shares. Collegium Pharmaceutical Inc shares valued at $626,171 were divested by the EVP & Chief Commercial Officer at a price of $38.21 per share. As a result of the transaction, Dreyer Scott now holds 103,613 shares, worth roughly $3.62 million.
Needham upgraded its Collegium Pharmaceutical Inc [COLL] rating to a Buy from a a Hold in a research note published recently. A number of analysts have revised their coverage, including H.C. Wainwright’s analysts, who increased its forecast for the stock in late July from “a Neutral” to “a Buy”. Jefferies also remained covering COLL and has increased its forecast on June 07, 2024 with a “Buy” recommendation from previously “Hold” rating. Piper Sandler revised its rating on May 10, 2024. It rated COLL as “a Neutral” which previously was an “an Overweight”.
Price Performance Review of COLL
On Monday, Collegium Pharmaceutical Inc [NASDAQ:COLL] saw its stock fall -6.43% to $34.92. Over the last five days, the stock has lost -7.50%. Collegium Pharmaceutical Inc shares have fallen nearly -3.54% since the year began. Nevertheless, the stocks have risen 21.88% over the past one year.
How much short interest is there in Collegium Pharmaceutical Inc?
A steep rise in short interest was recorded in Collegium Pharmaceutical Inc stocks on 2025-08-29, growing by 0.11 million shares to a total of 4.32 million shares. Yahoo Finance data shows the prior-month short interest on 2025-07-31 was 4.22 million shares. There was a rise of 2.52%, which implies that there is a positive sentiment for the stock.
